每周一次艾塞那肽对伴或不伴心衰的2型糖尿病患者及心衰相关结局的影响:EXSCEL试验分析
艾塞那肽组全因死亡风险降低(HR 0.86,95%CI 0.77-0.97),但该获益在基线心衰患者中减弱(交互P=0.031);首次加重度心衰住院风险降低(HR 0.82,95%CI 0.68-0.99,P=0.038)。
要点
- 艾塞那肽组全因死亡风险降低,但获益主要见于无基线心衰患者。
- 基线心衰患者中艾塞那肽对全因死亡和心衰住院的获益减弱。
- 艾塞那肽减少首次及复发性心衰住院的复合事件。
核心结论
- 在EXSCEL试验中,艾塞那肽在伴或不伴心衰患者中耐受性良好,但基线心衰患者中全因死亡和首次心衰住院的获益减弱。
研究设计与样本
- 按基线心衰状态(不论射血分数)分析艾塞那肽对全因死亡、主要不良心脏事件各组分、首次心衰住院和复发性心衰住院的影响。
- 另对基线射血分数保留或降低的人群进行亚组分析。
主要发现
- 2389例(16.2%)基线合并心衰;与无基线心衰者相比,基线心衰患者年龄更大,男性和白人比例更高,其他心血管疾病负担更重。
- 总体艾塞那肽组全因死亡发生率降低(HR 0.86,95%CI 0.77-0.97),全因死亡或心衰住院复合终点降低(HR 0.89,95%CI 0.80-0.99)。
- 基线心衰患者中艾塞那肽未降低全因死亡(HR 1.05,95%CI 0.85-1.29),无基线心衰患者中死亡风险降低(HR 0.79,95%CI 0.68-0.92),交互P=0.031。
- 无基线心衰患者中全因死亡或心衰住院降低(HR 0.81,95%CI 0.71-0.93),基线心衰患者中未见降低(HR 1.07,95%CI 0.89-1.29),交互P=0.015。
- 艾塞那肽组首次加复发性心衰住院较安慰剂组降低(HR 0.82,95%CI 0.68-0.99,P=0.038)。
临床怎么用
- 对无基线心衰的2型糖尿病患者,艾塞那肽可能降低全因死亡及心衰住院风险。
- 对基线合并心衰的2型糖尿病患者,不应期望艾塞那肽带来死亡或心衰住院获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baseline heart failure (HF) status. EQW's effects on secondary end points based on HHF status have not been reported. The objective was to explore the effects of EQW on secondary end points in patients with and without baseline HF and test the effects of EQW on recurrent HHF events. METHODS: The prespecified analysis of the randomized controlled EXSCEL trial, which enrolled patients with type 2 diabetes mellitus with and without additional cardiovascular disease, analyzed EQW effects on all-cause death, each major adverse cardiac event component, first HHF, and repeat HHF, by baseline HF status (regardless of ejection fraction). A subgroup analysis of the population stratified by preserved or reduced baseline ejection fraction was performed. RESULTS: Of 14 752 EXSCEL participants, 2389 (16.2%) had HF at baseline. Compared with those without HF at baseline, patients with preexisting HF were older, and more likely to be male and white, with a higher burden of other cardiovascular diseases. Overall, those assigned to EQW had a lower incidence of all-cause death (hazard ratio [HR], 0.86 [95% CI, 0.77-0.97]) and the composite outcome of all-cause death or HHF (HR, 0.89 [95% CI, 0.80-0.99]). When stratified by presence or absence of baseline HF, there was no observed reduction in all-cause death with EQW with baseline HF (HR, 1.05 [95% CI, 0.85-1.29]), while the risk of mortality was reduced with EQW in the no-HF group (HR, 0.79 [95% CI, 0.68-0.92]) with an interaction P value of 0.031. The reduction in all-cause death or HHF seen with EQW in patients without baseline HF (HR, 0.81 [95% CI, 0.71-0.93]) was not seen in patients with baseline HF (HR, 1.07 [95% CI, 0.89-1.29]; interaction P=0.015). First, plus recurrent, HHF was reduced in the exenatide group versus placebo (HR, 0.82 [95% CI, 0.68-0.99]; P=0.038). CONCLUSIONS: In EXSCEL, the use of EQW in patients with or without HF was well tolerated, but benefits of EQW on reduction in all-cause death and first hospitalization for HF were attenuated in patients with baseline HF. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov. Unique identifier: NCT01144338.
引用
- Fudim M, White J, Pagidipati NJ, et al. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. Circulation. 2019. PMID: 31542942. doi:10.1161/CIRCULATIONAHA.119.041659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。